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o A significant number of preclinical and clinical studies pointed out that Multidrug Resistance-
associated Protein (MRP) mediated efflux transport plays an important role in the systemic and
tissue exposure profiles of many drugs, their metabolites and endogenous compounds like bile
acids1. A problem associated with the MRP subfamily is that the exact role of the various isoforms
in drug disposition is relatively hard to study, at least partly due to lack of potent and selective
MRP inhibitors2.
o The purpose of this study was to identify selective Mrp3 inhibitors in rat hepatocytes in 
suspension using the oil spin method3. 
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o Several strong Mrp3 inhibitors were identified using rat hepatocytes in suspension in this 
optimized in vivo relevant in vitro assay.
o Human hepatocytes are currently used which will allow to elucidate cross-species differences for 
MRP3 inhibition.
o SAR modeling will enable in silico screening larger libraries for more and potent MRP3 inhibitors.
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Figure 2: Graphical presentation of the optimized assay used to screen for Mrp3 inhibitors in rat 
hepatocytes in suspension. The Spectrum Collection (MSDiscovery) was used as compound library.   
In total 1900 compounds were screened.
Figure 4: Overview of all compounds
registered as positive hit. Based on
3min and 5min intracellular CDF
levels, AUC values were calculated
and expressed as % of the AUC
obtained for benzbromarone (100%).
A 50% cut-off was chosen to
distinguish between non-inhibitors
and inhibitors. In total there was a
2% hit percentage (36 hits VS 1900
compounds screened). (n=2)
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Figure 1: Graphical presentation
of the purpose of this study. The
aim is to identify selective
inhibitors for Mrp3 using a
screening approach in rat
hepatocytes in suspension.
* In suspension, hepatic Mrp2 
activity and expression is very 
low due to internalisation
implying that the present 
approach will elucidate Mrp3 
inhibitors4.
Mrp3
Mrp2
CYP-450 
enzyme
Bile
Compound library
Hepatocyte
Blood
*
% inhibition compared to Benzbromarone
?
200µL Cell suspension
700µL Oil mixture
300µL 8% NaCl solution
14462 x g 
3min
Snap freeze 
tubes in mixture 
of dry ice and 
ethanol
-------------
Figure 3: Graphical representation of time dependent Mrp3 mediated CDF efflux in rat
hepatocytes in suspension. Based on the results, 3min and 5 min were selected as time points for
screening. The area under the curve (AUC) of benzbromarone subtracted by the AUC of the
control condition represents 100% inhibition. (n=3)
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AUC2
AUC1
AUC1-AUC2 = 100% inhibition
Incubation
CDFDA will react with intracellular 
esterases and CDF, 
benzbromarone or possible Mrp3 
inhibitor with transporter
100% inhibition (as depicted in Figure 3)
